Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track REPL with free AI briefings, catalyst countdowns, and dilution alerts.

REPL · Replimune Group, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$307.8M Cash on Hand
15mo Cash Runway
36.1% Short Interest
$25.5 Analyst Target (6)
Follow REPL by email Get an email when REPL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about REPL, unsubscribe in one click. Privacy

📣 What REPL Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Vusolimogene Oderparepvec Advanced Melanoma Phase 3 · NCT06264180 Recruiting
Single-agent chemotherapy Advanced Melanoma Phase 3 · NCT06264180 Recruiting
Sturlimogene Erparepvec Metastatic Uveal Melanoma Phase 2/3 · NCT06581406 Recruiting
Oncolytic Herpes Simplex Virus-1 Expressing… Refractory Metastatic Colorectal Cancer Phase 2 · NCT05733611 Terminated

Also used in these trials (approved or third-party drugs, not REPL's own candidates): Ipilimumab, Nivolumab, Relatlimab, Pembrolizumab, Atezolizumab, Pegfilgrastim, Filgrastim, Durvalumab, Cemiplimab, Bevacizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

REPL holds $307.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $61.7M/quarter from operations, an estimated runway of 15 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 50 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when REPL files for a raise →

👥 Who Owns REPL

Insiders 3% Institutions (259 holders) 97% Public and other holders 0%
HolderTypeShares% of sharesAs of
Baker Bros. Advisors LP Institution (13G, 5%+) 11,075,336 11.68% 2026-08-09
Blackrock Inc. Institution (13F) 8,799,007 9.28% 2026-09-30
RTW Investments, LP Institution (13G, 5%+) 7,356,916 7.76% 2026-03-31
Montanova Capital, LLC Institution (13G, 5%+) 6,609,000 6.97% 2026-07-30
Boxer Capital Management, LLC Institution (13F) 4,278,159 4.51% 2026-09-30
Suvretta Capital Management, LLC Institution (13G, 5%+) 4,221,836 4.45% 2026-03-31
State Street Corporation Institution (13F) 4,174,260 4.40% 2026-09-30
Marshall Wace LLP Institution (13F) 3,815,373 4.02% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 3,395,553 3.58% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 3,322,524 3.50% 2026-09-30
AQR Capital Management, LLC Institution (13F) 2,308,478 2.44% 2026-09-30
Philip Astley-Sparke
Director · +75,000 options
Insider 1,362,414 1.44% 2026-08-20

Share count 94,800,404 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-09
filed 2026-11-10
SLATTERY JOSEPH P
Sale (S) 5,200 $21.80 1,467
2026-11-02
filed 2026-11-03
Dhingra Kapil
Option exercise (M) 43,169 $1.75 43,169
2026-11-02
filed 2026-11-03
Dhingra Kapil
Sale (S) 21,500 $19.00 21,669
2026-11-02
filed 2026-11-03
Dhingra Kapil
Option exercise (M) 43,169 – –
2026-08-20
filed 2026-08-24
Astley-Sparke Philip
Gift (G) 50,000 – 1,362,414

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-04-10 vusolimogene oderparepvec BLA -28.2% -19.5% -62.9%

Browse all historical PDUFA outcomes →

Get the full REPL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for REPL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.